Insulet (PODD)
(Delayed Data from NSDQ)
$201.39 USD
+2.52 (1.27%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $201.33 -0.06 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 261 - 280 ( 343 total )
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulet-Amgen 5 Year Deal for OmniPod A Strong Positive
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Inline Q3 on revs, EPS below expectations, next-gen OmniPod transition goes on
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Thank Goodness the Transition is Behind them; Full Speed Ahead
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulet Adds Medical Director With Artificial Pancreas Work and Other Extensive Expertise
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Initiating Coverage with a Buy Rating and $44 price target.
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Q2 inline, next gen OmniPod generating new interest, transitioning well
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
New pods appear well received, raising target to $33, lowering to HOLD on valuation
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Q1 inline, guidance maintained, reiterating BUY, raising PT to $28.00
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 3,200+ pump users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Q4 results inline, 2013 OmniPod guidance midpoint ahead of expectations
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 2,900+ pump users
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Integrated pump-CGM combo on horizon? New opportunities in 2013 and beyond
Provider: FELTL & COMPANY
Analyst: HAYNOR B